Trial Profile

A Phase II, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of M5049 in Hospitalized Participants With COVID-19 Pneumonia (ANEMONE)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 28 Dec 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Enpatoran (Primary)
Indications COVID-19 pneumonia; COVID-19 respiratory infection
Focus Adverse reactions; Therapeutic Use
Acronyms ANEMONE
Sponsors EMD Serono Research & Development Institute

Most Recent Events

14 Nov 2022 Results assessing the safety and efficacy of Enpatoran in Patients Hospitalized with COVID-19 Pneumonia presented at the ACR Convergence 2022
04 Jun 2022 Primary endpoint (Time to Recovery) has not been met according to the results presented at the 23rd Annual Congress of the European League Against Rheumatism
04 Jun 2022 Results presented at the 23rd Annual Congress of the European League Against Rheumatism

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com